Rod Raynovich's  Instablog

Rod Raynovich
Send Message
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 30 years executive experience including Abbott and JNJ and has been involved three successful start-ups. He has a B.S, from Penn State University and an MBA from... More
My company:
Raygent Capital
My blog:
  • Life Science Bull Market: Winners YTD In Diagnostics, Tools And Biopharm  0 comments
    May 7, 2013 6:38 PM | about stocks: HOLX, GHDX, ILMN, REGN

    Selected Life Science Stocks Continue to Outperform the Market: Up 30% and More

    Here is a portfolio summary of my picks and current assessment prior to the so-called "sell-off" zone May 8-24.

    Biopharmaceuticals Overbought

    Rayno Biopharma Portfolio

    We are still cautious on adding new biotech positions except stocks that were mentioned last month (see Alkermes ALKS, Array ARRY and Achillion ACHN). Many biotech MO stocks are well off their highs. All positions remain as HOLDS unless you want to raise a little cash. Albany Molecular (AMRI) is up 5%, a value play (PS 1.76) as more investors have discovered the CRO sector because more biotech companies are outsourcing R&D. AMRI is up more than 100% YTD and was added to the Portfolio on 2/10/11 at $4.68.

    Technicals rule at this point near the IBB top at $176.

    Here is a brief summary of our picks:

    Alexion (NASDAQ:ALXN) strong hold but way off top of $119.54.

    Astex (NASDAQ:ASTX) very speculative but with strong balance sheet.The stock is up 267% over one year.

    Amgen (NASDAQ:AMGN) strong hold.

    Biogen (NASDAQ:BIIB) strong hold.

    Cubist (CBST) strong hold.

    Exelixis (NASDAQ:EXEL) weak for trades only.

    Gilead (NASDAQ:GILD) hit an intermediate top Friday so take a little off, but hard to buy on weakness. Reiterated guidance.

    Immunogen (NASDAQ:IMGN) strong hold.

    Optimer (NASDAQ:OPTR) strong hold.

    Pharmacyclics (NASDAQ:PCYC) off all time high of $95.85. MO stock weak technically.

    Regeneron (NASDAQ:REGN) high flyer MO stock hit with profit taking after blow-off last week.

    Seattle Genetics (NASDAQ:SGEN) strong hold.

    Viropharma (VPHM) strong hold.

    We put on a paired trade Alkermes (NASDAQ:ALKS) long at $23 with Infinity (NASDAQ:INFI) short at $48 and closed it out but left ALKS long.

    Some Big Winners in Diagnostics

    Rayno Diagnostics and Tools-Awaiting Q1 Results

    Many Rayno Diagnostics and Tools stocks have made new highs recently despite the sector being less frothy than biopharmaceuticals. These stocks are more pinned to financial results and dependent on a steady stream of new products. Important themes are genomics, molecular diagnostics, companion diagnostics and novel assays for infectious diseases like Flu and HCV. Recently we added Genomic Health (GHDX) a play in personalized medicine for cancer at $28.5 and Hologic (NASDAQ:HOLX) at $21.60.

    Hologic, a broad -based diagnostics and women's health play has been a laggard and is selling off 4% today after the earnings release. Hologic results include the acquired GenProbe with Q2 revenues of $160.5M. The fiscal Q2 net loss was $51.1M or $0.19 per share. Revenue guidance was cut to $2.53B-2..55B from $2.61-$2.64B. Women's health and imaging sales were mixed with Thin Prep Sales weak, so it appears that the GenProbe acquisition was the right move. We were a bit early into this stock but would still bet on a turnaround with the PE of 11.41 and a P/S of 2.56. This also has been a volatile stock with a lot of selling going on lately so we need to hold near the $20 level with some downside to $19.

    Here is a quick review of our portfolio:

    Abaxis (ABAX) big winner,strong hold, buy on weakness, off top of $48.

    Alere (NYSE:ALR) reiterated buy at $19 after collapse of stock. Value play and turnaround now at $27.

    Cardiovascular System (NASDAQ:CSII) strong hold for Company focused in minimally invasive cardiovascular disease.

    Cepheid (CPHD) top molecular diagnostics play, strong hold, despite valuation.

    Exact Sciences (NASDAQ:EXAS) long term play for molecular test for colon cancer.

    Illumina (ILMN) big winner,up 11 pts since early April. Gotta be in this premier sequencing play, buy on weakness.

    Neogen (NASDAQ:NEOG) strong hold at new highs at $52. Niche products for food and animal safety.

    Qiagen (NASDAQ:QGEN) turnaround molecular diagnostic play has been disappointing. Hold is only for the patient.

    Quidel (NASDAQ:QDEL) big winner,off its highs near $25. Strong hold.

    Response Genetics (NASDAQ:RGDX) turnaround play. A wait and see hold. Tightly held.

    Sequenom (NASDAQ:SQNM) a laggard, but pure play in prenatal genetic disorders.

    ThermoFisher (NYSE:TMO) huge winner up 33 pts. since July. Tools company acquiring major diagnostics companies. Still has value at PE 24 and P/S at 2.34.

    For a complete summary of key financial metrics se our March 21 posting that summarizes 2012 Results.

    Disclosure: I am long ILMN, RGDX, CSII.

    Stocks: HOLX, GHDX, ILMN, REGN
Back To Rod Raynovich's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.